OPTN OptiNose

Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal

Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal

YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2018 in the medium-sized company category.

“We are proud of every single person on the Optinose team for creating a Philadelphia Business Journal ‘Best Place to Work,’ because we know that our company’s wonderful culture is a result of the ownership that is felt by every colleague,” said Peter Miller, CEO of Optinose. “Building a company where people love to come to work has been a priority for us ever since we started Optinose.”

“Recognition as a ‘Best Place to Work’ means our team is succeeding in creating the shared culture we all aspire to, one that is based on core values,” added Ramy Mahmoud, President and Chief Operating Officer of Optinose. “Even with our rapid growth, our colleagues are successfully sustaining core values such as Friendship, Authenticity, Openness, Possibility Thinking, and of course ‘One Mission.’ These shared values are reflected in how we work every day and we believe they have been essential to our track record of success in both developing and commercializing innovative new products.”

Over the past year, Optinose has grown from 22 to more than 90 colleagues globally, with over 60 based in the headquarters in Yardley. It has also achieved a second FDA product approval, launched an important new product (XHANCETM), and completed a successful IPO.  More information about the shared purpose that unites the people of Optinose is , and more information about career opportunities is .

The Philadelphia Business Journal names companies to its “Best Places to Work” list using a rigorous scientific process based on responses to an independent employee engagement survey conducted by Quantum Workplace. As a finalist, Optinose’s culture was favorably ranked by employees in areas including work environment, people, personal growth, and professional development. 

About Optinose

Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit or follow us on and .

Optinose Investor Contact

Jonathan Neely

 

267.521.0531

Optinose Media Contact

Kate Traynor, Sloane & Company

 

212.446.1871

 

EN
02/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptiNose

 PRESS RELEASE

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results a...

Optinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended Dece...

 PRESS RELEASE

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceut...

 PRESS RELEASE

Optinose Announces Reporting Date for Fourth Quarter and Full Year 202...

Optinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast to be held March 20, 2025, at 8:00 a.m. Eastern Time YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company’s leadership team w...

 PRESS RELEASE

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Ne...

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth quarter n...

 PRESS RELEASE

Optinose Announces 1-for-15 Reverse Stock Split

Optinose Announces 1-for-15 Reverse Stock Split YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Standard Time, on December 30, 2024. Beginning with the opening of trading on December 31, 2024, Optinose’s common stock will trade on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis under a new CUSIP number 68404V209 and Optinose’s existing trading s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch